Abstract
Objective: To investigate the prognostic value of p53 and HER-2/neu overexpression in endometrial cancer. Study Design: p53 and HER-2/neu immunostaining was performed in 114 paraffin-embedded specimens of endometrial cancer diagnosed and treated between 1990 and 1997. Nuclear p53 and membrane HER-2/neu immunostaining were used. Results: p53 and HER-2/neu overexpression was observed in 17 cases (14.9%) and in 19 cases (16.7%), respectively. In univariate analysis p53 (P < 0.001) and HER-2/neu (P = 0.018) overexpression had a positive correlation with a high risk of recurrence. In multivariate analysis, age (P < 0.001), FIGO stage (P < 0.001), differentiation (P = 0.013), non-endometrioid subtypes (P < 0.001) and p53 overexpression (P < 0.001), but not HER-2/neu overexpression, were independent prognostic indicators of recurrence. Simultaneous p53 and HER-2/neu overexpression made worse the prognostic (P < 0.001). Conclusions: p53 overexpression was an independent predictor of recurrent disease in endometrial cancer. HER-2/neu overexpression had a more limited effect but enhance the effect of p53.
Original language | English (US) |
---|---|
Pages (from-to) | 103-108 |
Number of pages | 6 |
Journal | European Journal of Obstetrics and Gynecology and Reproductive Biology |
Volume | 98 |
Issue number | 1 |
DOIs | |
State | Published - 2001 |
Keywords
- Endometrial cancer
- HER-2/neu
- Immunohistochemistry
- Prognostic factors
- Survival
- p53
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynecology